Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Piramal Pharma Limited ( (IN:PPLPHARMA) ) has shared an update.
Piramal Pharma Limited’s board has approved the audited standalone and consolidated financial statements and results for the quarter and full year ended 31 March 2026, in line with SEBI listing requirements, and plans to publish these in newspapers as mandated. The board also moved to reinforce its leadership bench, backing the re-appointment of Executive Director and Chairperson Nandini Piramal, Executive Director Peter DeYoung, and independent directors Sridhar Gorthi and Peter Stevenson—whose term will continue beyond age 75—subject to shareholder approval, underscoring continuity in governance and strategic direction.
More about Piramal Pharma Limited
Piramal Pharma Limited is an India-based pharmaceutical company focused on developing, manufacturing and supplying pharma products and services. Listed on Indian stock exchanges under the symbol PPLPHARMA, it operates through standalone and consolidated entities, serving both domestic and international markets across the broader healthcare and life sciences sector.
Average Trading Volume: 217,020
Technical Sentiment Signal: Hold
Current Market Cap: 219.9B INR
For detailed information about PPLPHARMA stock, go to TipRanks’ Stock Analysis page.